IMUNON, Inc. announced on February 10, 2025, the appointment of Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer, effective February 18, 2025. Dr. Faller brings over 30 years of industry, academic, and laboratory experience, with specialized expertise in oncology and immunology.
In his new role, Dr. Faller will lead the company’s clinical strategy, including advancing its lead program, IMNN-001, for the treatment of newly diagnosed advanced ovarian cancer. IMNN-001 is on track to enter a Phase 3 pivotal trial in the first quarter of 2025.
Dr. Faller's extensive background includes leadership roles at Skyhawk Therapeutics and Takeda, where he oversaw the development of late-stage therapies in oncology. In connection with his appointment, Dr. Faller was granted inducement stock options to purchase 100,000 shares of common stock, effective February 18, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.